The Hidden Costs and Strategic Risks Behind CGT Manufacturing Decisions

In this segment of During Cell & Gene Live, “Distributed Manufacturing for CGT: Rent, Lease, or Buy in an Era of Overcapacity?,” experts Emily Moran, Founder, 3LB Consulting, LLC and Sugu Patro, Ph.D., Senior Vice President Global Process Development at Kite, a Gilead Company examined how CGT companies can balance capital efficiency, operational control, and long-term scalability when choosing between leasing, partnering, or building manufacturing capabilities. The panelists highlighted the significant downstream risks of prioritizing speed or low cost over technical fit while also exploring how emerging automated manufacturing platforms could help expand decentralized and point-of-care manufacturing models in the future.